+444.7%
APLD vs MRNA
-9.1%
+453.8%
-81.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.5% | +5.4% | -2.9% | +1.9% |
| 7D | +0.2% | -1.1% | +1.3% | +0.3% |
| 30D | -15.2% | +126.1% | -141.3% | -31.1% |
| 3M | -36.3% | +190.0% | -226.3% | -53.2% |
| 6M | -7.4% | +157.2% | -164.6% | -29.3% |
| YTD | +7.7% | +388.2% | -380.5% | -35.6% |
| 1Y | +53.8% | +467.0% | -413.3% | -13.6% |
| 3Y | +407.1% | +36.1% | +371.0% | +328.4% |
| All | +444.7% | -9.1% | +453.8% | +334.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling